| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year |
| 23 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) any Returning Shares will beco... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
NEPHRO CRRT clinical study expected to be completed this year |
| 23 Mar 2026 |
8-K: Results of Operations and Financial Condition
Previously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in |
| 16 Mar 2026 |
8-K: Unregistered Sales of Equity Securities
As previously disclosed, on March 31, 2025, Talphera, Inc., or the Company, entered into a securities purchase agreement, or the Purchase Agreement, with several institutional investors and a member of management (collectively, the Purch... |
| 13 Mar 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. |
| 24 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) any Returning Shares will beco... |
| 22 Oct 2025 |
8-K: Unregistered Sales of Equity Securities; Other Events
As previously disclosed, on March 31, 2025, Talphera, Inc., or Talphera, entered into a securities purchase agreement, or the Purchase Agreement, with several institutional investors and a member of management (collectively, the Purchase... |
| 16 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
| 10 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This Securities Purchase Agreement (this “Agreement”) is dated as of September 7, 2025, by and between Talphera, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including i... |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition
New sites accelerate registrational study enrollment - 15 patients have been enrolled in the NEPHRO study which remains on track with completion projected by the end of the year |
| 05 Jun 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 14 May 2025 |
8-K: Results of Operations and Financial Condition
Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million |
| 02 Apr 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This Securities Purchase Agreement (this “Agreement”) is dated as of March 31, 2025, by and between Talphera, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its ... |
| 31 Mar 2025 |
8-K: Results of Operations and Financial Condition
The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 |
| 11 Dec 2024 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 29 Nov 2024 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 13 Nov 2024 |
8-K: Results of Operations and Financial Condition
Five sites actively screening with multiple patients having completed the study; two additional institutions expected to begin screening in the fourth quarter totaling seven active sites |
Loading...